RecruitingNot ApplicableNCT04424719

Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)

Sponsor

Institut Curie

Enrollment

700 participants

Start Date

Jul 8, 2020

Study Type

INTERVENTIONAL

Conditions

Uveal Melanoma

Summary

Biomarkers search for early diagnosis of liver metastases in patients with uveal melanoma who benefit from a follow-up tailored to their personalized risk of relapse.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study follows patients with uveal melanoma (a type of eye cancer) who are at high risk of the cancer spreading to other organs, to evaluate whether a personalized monitoring schedule (including regular blood and imaging tests) can detect a relapse earlier and improve survival. **You may be eligible if...** - You are 18 or older - You have been diagnosed with uveal melanoma classified as high risk for spreading (based on tumor size or specific chromosome abnormalities: chromosome 3 or 8) - Treatment of your primary eye tumor was completed within the last 2 months - You can attend the required visits and blood draws **You may NOT be eligible if...** - You do not have French social insurance coverage - Your social, medical, or psychological situation makes participation impossible Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBlood test

High risk patients are referred for the medical oncology consultation to organize oncological surveillance after general staging of the disease. Signature of the informed consent of SALOME study, inclusion in the study and risk-adjusted surveillance schedule : (i) Liver MRI every 6 months performed at the expert center for UM (according to guidelines). (ii) For enucleated patients, a blood sample (3 x 6 ml EDTA tubes) is taken every 6 months according to the schedule below. Plasma and mononucleated cells will be isolated and preserved for bio-markers research. * M0 : during the first medical oncology visit. * At each imaging assessment, every 6 months for at least 5 years (M6 to M60) and 10 years maximum (M120). * At the diagnosis of metastasis. * At each significant event during the metastatic disease (surgery, treatment response or progression).